跳转至内容
Merck
CN
所有图片(2)

文件

489478

Sigma-Aldrich

LSD1 Inhibitor III, CBB1007

The LSD1 Inhibitor III, CBB1007 controls the biological activity of LSD1. This small molecule/inhibitor is primarily used for Cell Structure applications.

登录查看公司和协议定价

别名:
LSD1 Inhibitor III, CBB1007, LSD Inhibitor III, BHC110 Inhibitor III, Methyl-3-(4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl)-5-((4-carbamimidoylpiperazin-1-yl)methyl)benzoate, 3TFA, KDM1 Inhibitor III, Histone Lysine Demethylase Inhibitor V, LSD Inhibitor III, Methyl-3-(4-(4-carbamimidoylbenzoyl)piperazine-1-carbonyl)-5-((4-carbamimidoylpiperazin-1-yl)methyl)benzoate, 3TFA, KDM1 Inhibitor III, Histone Lysine Demethylase Inhibitor V, BHC110 Inhibitor III
经验公式(希尔记法):
C27H34N8O4 · 3C2HF3O2
分子量:
876.68
MDL编号:
UNSPSC代码:
12352200

质量水平

检测方案

≥99% (HPLC)

形式

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
desiccated (hygroscopic)
protect from light

颜色

white

溶解性

DMSO: 50 mg/mL

运输

ambient

储存温度

−20°C

SMILES字符串

NC(N1CCN(CC2=CC(C(N3CCN(C(C4=CC=C(C(N)=N)C=C4)=O)CC3)=O)=CC(C(OC)=O)=C2)CC1)=N

一般描述

A cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 µM for hLSD1) and efficiently blocks LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 µM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC50 ≤ 5 µM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC50 ≤ 3.74 µM). Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC50 >100 µM).

Note: the molecular weight is lot-specific and can be found on the vial label.
A cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 µM for hLSD1) and efficiently blocks LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 µM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC50 ≤ 5 µM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC50 ≤ 3.74 µM). Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC50 >100 µM).

包装

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

外形

Supplied as a trifluoroacetate salt.

重悬

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

其他说明

Wang, J., et al. 2011. Cancer Res.71, 7238.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门